The Journal of antimicrobial chemotherapy
-
J. Antimicrob. Chemother. · Jan 2012
Tigecycline accelerates staphylococcal-infected burn wound healing through matrix metalloproteinase-9 modulation.
We investigated the in vivo efficacy of tigecycline, a new glycylcycline (a tetracycline derivative), in the management of methicillin-resistant Staphylococcus aureus (MRSA)-infected experimental surgical wounds in rats. The main outcome measures were quantitative bacterial culture, histological examination and immunohistochemical expression of matrix metalloproteinase-9 (MMP-9) and collagen IV. ⋯ Tigecycline, besides its antimicrobial activity, exerts an important modulatory effect on MMP-9, accelerating wound healing in staphylococcal-infected burns.
-
J. Antimicrob. Chemother. · Dec 2011
Antifungal use influences Candida species distribution and susceptibility in the intensive care unit.
Antifungal prescription practices have changed over the last decade, and the impact of these changes is unclear. Our objective here was to evaluate the effect of antifungal drug use on the distribution and drug susceptibility of Candida spp. in a French intensive care unit (ICU). ⋯ Antifungal drug use in the ICU is associated with major changes in the distribution and drug susceptibility of Candida spp.
-
J. Antimicrob. Chemother. · Nov 2011
Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales.
The third-generation cephalosporins recommended in national guidelines are amongst the last remaining effective agents for treatment of gonorrhoea. This study characterizes gonococcal isolates with decreased cefixime susceptibility from England and Wales. ⋯ The emergence of a clonal group of gonococci showing decreased susceptibility to cefixime in England and Wales highlights the need for continued surveillance.
-
J. Antimicrob. Chemother. · Nov 2011
Randomized Controlled Trial Multicenter Study Clinical TrialA randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
The primary aim of the RELIEF study was to evaluate the efficacy and safety of two sequential intravenous (iv)/oral regimens: moxifloxacin iv/oral versus piperacillin/tazobactam (TZP) iv followed by oral amoxicillin/clavulanate (AMC). ⋯ Once-daily iv/oral moxifloxacin monotherapy was clinically and bacteriologically non-inferior to iv TZP thrice daily followed by oral AMC twice daily in patients with cSSSIs.
-
J. Antimicrob. Chemother. · Nov 2011
Methicillin-susceptible Staphylococcus aureus ST398-t571 harbouring the macrolide-lincosamide-streptogramin B resistance gene erm(T) in Belgian hospitals.
Methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible S. aureus (MSSA), collected from 109 Belgian acute-care hospitals during a national survey in 2008, were investigated for macrolide-lincosamide (ML) resistance with particular emphasis on the analysis of erm(T)-carrying isolates. ⋯ The ML-streptogramin B ('MLS(B)') resistance genes erm(A) or erm(C) were detected in the majority of ML-resistant MRSA and MSSA isolates. The erm(T) gene was identified in MSSA ST398 isolates from five independent patients who lacked direct contact with livestock.